Page last updated: 2024-11-02
piracetam and Stroke
piracetam has been researched along with Stroke in 44 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and twenty-eight patients with poststroke seizures were randomly allocated to treatment with either levetiracetam (LEV) or sustained-release carbamazepine (CBZ) in a multicenter randomized open-label study." | 9.16 | Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). ( Bosco, D; Consoli, D; Galati, F; Neri, G; Ottonello, GA; Passarella, B; Perticoni, GF; Plastino, M; Postorino, P; Ricci, S; Toni, D, 2012) |
| "Twenty-four stroke patients with aphasia were randomly allocated to 2 groups: 12 patients received 2400 mg piracetam twice daily, 12 placebo." | 9.09 | Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. ( Heiss, WD; Karbe, H; Kessler, J; Thiel, A, 2000) |
| "Electroencephalographic and clinical effects of piracetam in post-stroke aphasia were evaluated in a prospective, randomized, double-blind, placebo-controlled trial." | 9.09 | Restitution of alpha-topography by piracetam in post-stroke aphasia. ( Heiss, WD; Kessler, J; Mielke, R; Szelies, B, 2001) |
| "We performed a systematic review and meta-analysis to assess whether piracetam facilitates the rehabilitation of language performance in post-stroke patients." | 8.93 | Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ( Chen, Z; Luo, B; Wei, R; Zhang, J, 2016) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 8.88 | Piracetam for acute ischaemic stroke. ( Cantisani, TA; Celani, MG; Ricci, S; Righetti, E, 2012) |
| " The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection." | 8.87 | Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. ( Belcastro, V; Pierguidi, L; Tambasco, N, 2011) |
| "Piracetam and its derivatives demonstrate neuroprotective efficacy in experimental stroke, but our findings raise concerns about the amount of available data, the quality of the studies and publication bias." | 8.84 | A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke. ( Macleod, MR; Sena, ES; Wheble, PC, 2008) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 8.83 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2006) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 8.81 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2002) |
| "We studied whether the administration of piracetam in acute, presumed ischemic stroke affects case fatality and functional outcome." | 8.80 | Piracetam in acute stroke: a systematic review. ( Cantisani, TA; Celani, MG; Ricci, S; Righetti, E, 2000) |
| "Randomised trials comparing piracetam with control, with at least mortality reported and entry to the trial within approximately 48 hours of stroke onset." | 8.80 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2000) |
| " In this study, we evaluated the effects of phenobarbital and levetiracetam on PR-QTc intervals in patients with post-stroke seizures." | 7.80 | Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure. ( Albertini, G; De Sarro, G; Gallelli, L; Gratteri, S; Iemolo, F; Manes, MT; Mercuri, NB; Quirino, G; Sanzaro, E; Scaglione, F; Siniscalchi, A, 2014) |
| "Stroke is the most common cause of seizures in the elderly." | 6.73 | Levetiracetam monotherapy for late poststroke seizures in the elderly. ( Gomceli, YB; Inan, LE; Kutlu, G; Unal, Y, 2008) |
| "Piracetam was significantly superior to ASA in the secondary endpoint (P=0." | 6.69 | Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. ( Evers, S; Fischer, M; Grotemeyer, KH; Husstedt, IW, 2000) |
| "One hundred and twenty-eight patients with poststroke seizures were randomly allocated to treatment with either levetiracetam (LEV) or sustained-release carbamazepine (CBZ) in a multicenter randomized open-label study." | 5.16 | Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). ( Bosco, D; Consoli, D; Galati, F; Neri, G; Ottonello, GA; Passarella, B; Perticoni, GF; Plastino, M; Postorino, P; Ricci, S; Toni, D, 2012) |
| "Due to too few participants, no conclusions could be drawn regarding the ability of levetiracetam to prevent poststroke seizures." | 5.15 | Early treatment after stroke for the prevention of late epileptic seizures: a report on the problems performing a randomised placebo-controlled double-blind trial aimed at anti-epileptogenesis. ( Aldenkamp, AP; de Krom, MC; Lodder, J; van Raak, EP; van Tuijl, JH, 2011) |
| "Twenty-four stroke patients with aphasia were randomly allocated to 2 groups: 12 patients received 2400 mg piracetam twice daily, 12 placebo." | 5.09 | Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. ( Heiss, WD; Karbe, H; Kessler, J; Thiel, A, 2000) |
| "Electroencephalographic and clinical effects of piracetam in post-stroke aphasia were evaluated in a prospective, randomized, double-blind, placebo-controlled trial." | 5.09 | Restitution of alpha-topography by piracetam in post-stroke aphasia. ( Heiss, WD; Kessler, J; Mielke, R; Szelies, B, 2001) |
| "We performed a systematic review and meta-analysis to assess whether piracetam facilitates the rehabilitation of language performance in post-stroke patients." | 4.93 | Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ( Chen, Z; Luo, B; Wei, R; Zhang, J, 2016) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 4.88 | Piracetam for acute ischaemic stroke. ( Cantisani, TA; Celani, MG; Ricci, S; Righetti, E, 2012) |
| " The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection." | 4.87 | Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. ( Belcastro, V; Pierguidi, L; Tambasco, N, 2011) |
| "Pharmacotherapy of aphasia had been discussed for the last twenty years with first bromocriptine and amphetamine and then serotoninergic, GABAergic and cholinergic agents." | 4.84 | Pharmacotherapy of aphasia: myth or reality? ( de Boissezon, X; de Boysson, C; Démonet, JF; Peran, P, 2007) |
| "Piracetam and its derivatives demonstrate neuroprotective efficacy in experimental stroke, but our findings raise concerns about the amount of available data, the quality of the studies and publication bias." | 4.84 | A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke. ( Macleod, MR; Sena, ES; Wheble, PC, 2008) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 4.83 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2006) |
| "The main conclusion of this review is that drug treatment with piracetam may be effective in the treatment of aphasia after stroke." | 4.81 | Pharmacological treatment for aphasia following stroke. ( Enderby, P; Greener, J; Whurr, R, 2001) |
| "There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials." | 4.81 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2002) |
| "We studied whether the administration of piracetam in acute, presumed ischemic stroke affects case fatality and functional outcome." | 4.80 | Piracetam in acute stroke: a systematic review. ( Cantisani, TA; Celani, MG; Ricci, S; Righetti, E, 2000) |
| "Randomised trials comparing piracetam with control, with at least mortality reported and entry to the trial within approximately 48 hours of stroke onset." | 4.80 | Piracetam for acute ischaemic stroke. ( Cantisani, AT; Celani, MG; Ricci, S; Righetti, E, 2000) |
| " In this study, we evaluated the effects of phenobarbital and levetiracetam on PR-QTc intervals in patients with post-stroke seizures." | 3.80 | Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure. ( Albertini, G; De Sarro, G; Gallelli, L; Gratteri, S; Iemolo, F; Manes, MT; Mercuri, NB; Quirino, G; Sanzaro, E; Scaglione, F; Siniscalchi, A, 2014) |
| "The study aimed at the evaluation of clinical efficacy and safety of the neurotrophic medication omaron, a combination of piracetam and cinnarizin, in the early restoration period of ischemic stroke." | 3.76 | [Omaron in the rehabilitation of post stroke outpatients]. ( Chuprina, SE, 2010) |
| "Efficacy of omaron (a combination of piracetam 400 mg and cinnarizin 25 mg) has been studied 3 months after stroke in 90 post-stroke patients." | 3.75 | [Use of omaron in patients with post-stroke cognitive disorders]. ( Belavina, GR; Gusev, VV; Levin, IaI; Markin, SP; Parfenov, VA; Starchina, IuA; Vakhnina, NV, 2009) |
| "The aim of the present work was to compare the morphological changes occurring at the focus of experimental ischemic stroke treated with agents of the neurotrophic group (alpha-GPC, cerebrolysin), an agent with nootropic properties (piracetam), and a mixed-action agent (vinpocetine)." | 3.74 | Changes at the focus of experimental ischemic stroke treated with neuroprotective agents. ( Gaikova, ON; Onishchenko, LS; Yanishevskii, SN, 2008) |
| "The purpose of this study was to compare the morphological changes in the focus of ischemic stroke under the influence of the drugs of neurotrophic group (alpha-GPC, cerebrolysin), drugs possessing the nootropic properties (piracetam) and those with combined effect (vinpocetin)." | 3.73 | [Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs]. ( Gaĭkova, ON; Ianishevskiĭ, SN; Onishchenko, LS, 2006) |
| "We studied 400 patients with ischemic stroke, including 200 patients (the main group), who received 3 courses of phenotropil in the complex rehabilitation treatment in dosage 400 mg/day during 1 year after stroke." | 2.75 | [Efficacy of phenotropil in the rehabilitation of stroke patients]. ( Il'iaĭnen, EV; Koval'chuk, IV; Koval'chuk, VV; Melikhova, EV; Skoromets, AA; Stoianova, EG; Vysotskaia, ML, 2010) |
| "Stroke is the most common cause of seizures in the elderly." | 2.73 | Levetiracetam monotherapy for late poststroke seizures in the elderly. ( Gomceli, YB; Inan, LE; Kutlu, G; Unal, Y, 2008) |
| "Piracetam was significantly superior to ASA in the secondary endpoint (P=0." | 2.69 | Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. ( Evers, S; Fischer, M; Grotemeyer, KH; Husstedt, IW, 2000) |
| "Carbamazepine was the most chosen antiepileptic drug for secondary prophylaxis, followed by valproate acid, and levetiracetam." | 1.48 | [A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan]. ( Abe, S; Fukuma, K; Higashida, K; Ihara, M; Nagatsuka, K; Okuno, Y; Tanaka, T; Tomari, S; Toyoda, K; Yamagami, H, 2018) |
| "Perinatal arterial stroke is the most frequent form of cerebral infarction in children." | 1.46 | Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model. ( Auvin, S; Baud, O; Bonnin, P; Charriaut-Marlangue, C; Dupuis, N; Enderlin, J; Leger, PL; Morin, L; Perrotte, G, 2017) |
| "This was very atypical case of herpes simplex encephalitis characterized by a stroke-like episode, atypical MRI findings, and absence of cerebrospinal fluid pleocytosis." | 1.46 | Herpes simplex encephalitis presenting as stroke-like symptoms with atypical MRI findings and lacking cerebrospinal fluid pleocytosis. ( Fujita, N; Oyake, M; Tsuboguchi, S; Umeda, M; Umeda, Y; Wakasugi, T, 2017) |
| "Cerebral venous thrombosis is a rare entity in pregnancy and the postpartum period, with an incidence of 1:10,000 to 1:25,000." | 1.37 | Postpartum cerebral venous thrombosis. ( McCaulley, JA; Pates, JA, 2011) |
| "Drugs approved and used for treatment of stroke vary from country to country." | 1.35 | Publication bias perpetuates use of ineffective drugs in stroke. ( Prasad, K, 2009) |
| "Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury." | 1.34 | TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007) |
| "Older patients and patients with brain tumors or strokes were preferentially treated with LEV for prevention and/or management of seizures (all P < or = 0." | 1.34 | Levetiracetam use in critically ill patients. ( Meckler, JM; Privitera, MD; Shutter, LA; Szaflarski, JP; Szaflarski, M; Yates, SL, 2007) |
Research
Studies (44)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (52.27) | 29.6817 |
| 2010's | 21 (47.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Tsuboguchi, S | 1 |
| Wakasugi, T | 1 |
| Umeda, Y | 1 |
| Umeda, M | 1 |
| Oyake, M | 1 |
| Fujita, N | 1 |
| Higashida, K | 1 |
| Tanaka, T | 1 |
| Yamagami, H | 1 |
| Tomari, S | 1 |
| Fukuma, K | 1 |
| Okuno, Y | 1 |
| Abe, S | 1 |
| Nagatsuka, K | 1 |
| Toyoda, K | 1 |
| Ihara, M | 1 |
| Siniscalchi, A | 1 |
| Scaglione, F | 1 |
| Sanzaro, E | 1 |
| Iemolo, F | 1 |
| Albertini, G | 1 |
| Quirino, G | 1 |
| Manes, MT | 1 |
| Gratteri, S | 1 |
| Mercuri, NB | 1 |
| De Sarro, G | 1 |
| Gallelli, L | 1 |
| Janszky, J | 1 |
| Horvath, R | 1 |
| Komoly, S | 1 |
| Waheed, W | 1 |
| Nathan, MH | 1 |
| Allen, GB | 1 |
| Borden, NM | 1 |
| Babi, MA | 1 |
| Tandan, R | 1 |
| Zhang, J | 1 |
| Wei, R | 1 |
| Chen, Z | 1 |
| Luo, B | 1 |
| Morin, L | 1 |
| Enderlin, J | 1 |
| Leger, PL | 1 |
| Perrotte, G | 1 |
| Bonnin, P | 1 |
| Dupuis, N | 1 |
| Baud, O | 1 |
| Charriaut-Marlangue, C | 1 |
| Auvin, S | 1 |
| Kutlu, G | 1 |
| Gomceli, YB | 1 |
| Unal, Y | 1 |
| Inan, LE | 1 |
| Gusev, EI | 1 |
| Bogolepova, AN | 1 |
| Derev'yannykh, EA | 1 |
| Bel'skaya, GN | 1 |
| Knoll, EA | 1 |
| Krylova, LG | 1 |
| Popov, DV | 1 |
| Prasad, K | 1 |
| Parfenov, VA | 1 |
| Belavina, GR | 1 |
| Vakhnina, NV | 1 |
| Gusev, VV | 1 |
| Levin, IaI | 1 |
| Markin, SP | 1 |
| Starchina, IuA | 1 |
| Chuprina, SE | 1 |
| Belcastro, V | 2 |
| Pierguidi, L | 1 |
| Tambasco, N | 1 |
| Güngör, L | 1 |
| Terzi, M | 1 |
| Onar, MK | 1 |
| van Tuijl, JH | 1 |
| van Raak, EP | 1 |
| de Krom, MC | 1 |
| Lodder, J | 1 |
| Aldenkamp, AP | 1 |
| Koval'chuk, VV | 1 |
| Skoromets, AA | 1 |
| Koval'chuk, IV | 1 |
| Stoianova, EG | 1 |
| Vysotskaia, ML | 1 |
| Melikhova, EV | 1 |
| Il'iaĭnen, EV | 1 |
| McCaulley, JA | 1 |
| Pates, JA | 1 |
| Robins, A | 1 |
| Patel, M | 1 |
| Azim, A | 1 |
| Fernández-Torrón, R | 1 |
| Esteve-Belloch, P | 1 |
| Palma, JA | 1 |
| Riverol, M | 1 |
| Iriarte, J | 1 |
| Jungehulsing, GJ | 1 |
| Israel, H | 1 |
| Safar, N | 1 |
| Taskin, B | 1 |
| Nolte, CH | 1 |
| Brunecker, P | 1 |
| Wernecke, KD | 1 |
| Villringer, A | 1 |
| Ricci, S | 6 |
| Celani, MG | 5 |
| Cantisani, TA | 2 |
| Righetti, E | 5 |
| Magomedova, AKh | 1 |
| Magomedov, MM | 1 |
| Magomedova, AM | 1 |
| Magomaev, MF | 1 |
| Consoli, D | 1 |
| Bosco, D | 1 |
| Postorino, P | 1 |
| Galati, F | 1 |
| Plastino, M | 1 |
| Perticoni, GF | 1 |
| Ottonello, GA | 1 |
| Passarella, B | 1 |
| Neri, G | 1 |
| Toni, D | 1 |
| Asadullaev, MM | 1 |
| Saidvaliev, FS | 1 |
| Shermukhamedova, FK | 1 |
| Rizvonov, ZhK | 1 |
| Vakhabova, NM | 1 |
| Schmidtke, K | 1 |
| Cantisani, AT | 3 |
| Xerri, C | 1 |
| Zennou-Azougui, Y | 1 |
| Coq, JO | 1 |
| de Boissezon, X | 1 |
| Peran, P | 1 |
| de Boysson, C | 1 |
| Démonet, JF | 1 |
| Al-Bahrani, A | 1 |
| Taha, S | 1 |
| Shaath, H | 1 |
| Bakhiet, M | 1 |
| Onishchenko, LS | 2 |
| Gaĭkova, ON | 2 |
| Ianishevskiĭ, SN | 1 |
| Chan, S | 1 |
| Ros, S | 1 |
| You, KY | 1 |
| Nhem, S | 1 |
| Salle, JY | 1 |
| Dudognon, P | 1 |
| Daviet, JC | 1 |
| Szaflarski, JP | 1 |
| Meckler, JM | 1 |
| Szaflarski, M | 1 |
| Shutter, LA | 1 |
| Privitera, MD | 1 |
| Yates, SL | 1 |
| Wheble, PC | 1 |
| Sena, ES | 1 |
| Macleod, MR | 1 |
| Yanishevskii, SN | 1 |
| Kessler, J | 2 |
| Thiel, A | 1 |
| Karbe, H | 1 |
| Heiss, WD | 2 |
| Grotemeyer, KH | 1 |
| Evers, S | 1 |
| Fischer, M | 1 |
| Husstedt, IW | 1 |
| Handschu, R | 1 |
| Garling, A | 1 |
| Heuschmann, PU | 1 |
| Kolominsky-Rabas, PL | 1 |
| Erbguth, F | 1 |
| Neundörfer, B | 1 |
| Szelies, B | 1 |
| Mielke, R | 1 |
| Greener, J | 1 |
| Enderby, P | 1 |
| Whurr, R | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Clinical Trial of tDCS to Remediate Phonological Impairment in Aphasia[NCT06010030] | 200 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | |||
| Effects of tDCS in Language Recovery and Reorganization in Chronic Aphasia[NCT04166513] | 4 participants (Anticipated) | Interventional | 2019-12-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
12 reviews available for piracetam and Stroke
| Article | Year |
|---|---|
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Aphasia; Humans; Language Disorders; Piracetam; Randomized Controlled Trials as Topic; Stroke; Treat | 2016 |
[Effectiveness of nootropil in the treatment of patients with cerebral stroke].
Topics: Humans; Nootropic Agents; Piracetam; Stroke | 2008 |
Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.
Topics: Animals; Anticonvulsants; Brain Ischemia; Clinical Trials as Topic; Disease Models, Animal; Epilepsy | 2011 |
Piracetam for acute ischaemic stroke.
Topics: Acute Disease; Brain Ischemia; Fibrinolytic Agents; Humans; Neuroprotective Agents; Piracetam; Rando | 2012 |
Piracetam for acute ischaemic stroke.
Topics: Acute Disease; Brain Ischemia; Humans; Neuroprotective Agents; Piracetam; Stroke | 2002 |
Piracetam for acute ischaemic stroke.
Topics: Acute Disease; Brain Ischemia; Humans; Neuroprotective Agents; Piracetam; Stroke | 2006 |
Pharmacotherapy of aphasia: myth or reality?
Topics: Amphetamine; Aphasia; Bromocriptine; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; | 2007 |
A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke.
Topics: Animals; Disease Models, Animal; Neuroprotective Agents; Piracetam; Stroke | 2008 |
Piracetam for acute ischaemic stroke.
Topics: Brain Ischemia; Humans; Neuroprotective Agents; Piracetam; Stroke | 2000 |
Piracetam in acute stroke: a systematic review.
Topics: Acute Disease; Clinical Trials as Topic; Humans; Piracetam; Stroke; Time Factors; Treatment Outcome | 2000 |
Pharmacological treatment for aphasia following stroke.
Topics: Aphasia; Humans; Neuroprotective Agents; Piracetam; Randomized Controlled Trials as Topic; Stroke | 2001 |
Pharmacological treatment for aphasia following stroke.
Topics: Aphasia; Humans; Neuroprotective Agents; Piracetam; Randomized Controlled Trials as Topic; Stroke | 2001 |
Pharmacological treatment for aphasia following stroke.
Topics: Aphasia; Humans; Neuroprotective Agents; Piracetam; Randomized Controlled Trials as Topic; Stroke | 2001 |
Pharmacological treatment for aphasia following stroke.
Topics: Aphasia; Humans; Neuroprotective Agents; Piracetam; Randomized Controlled Trials as Topic; Stroke | 2001 |
Trials
10 trials available for piracetam and Stroke
| Article | Year |
|---|---|
Levetiracetam monotherapy for late poststroke seizures in the elderly.
Topics: Aged; Anticonvulsants; Drug Evaluation; Epilepsy; Female; Follow-Up Studies; Geriatrics; Humans; Lev | 2008 |
Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases?
Topics: Aphasia; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Piracetam; Single-Blind Method; | 2011 |
Early treatment after stroke for the prevention of late epileptic seizures: a report on the problems performing a randomised placebo-controlled double-blind trial aimed at anti-epileptogenesis.
Topics: Aged; Anticonvulsants; Double-Blind Method; Epilepsy; Female; Humans; Levetiracetam; Male; Multicent | 2011 |
[Efficacy of phenotropil in the rehabilitation of stroke patients].
Topics: Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piracetam; Recovery of Function; Sever | 2010 |
Levetiracetam in patients with central neuropathic post-stroke pain--a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticonvulsants; Cross-Over Studies; Double-Blind Method; Female; Humans; Levetiracetam | 2013 |
Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Female; Humans; | 2012 |
[Assessment of multimodal effect of cytoflavin in the acute brain stroke in patients with metabolic syndrome].
Topics: Administration, Intravenous; Aged; Antioxidants; Drug Combinations; Female; Flavin Mononucleotide; H | 2012 |
Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients.
Topics: Adolescent; Adult; Aged; Aphasia; Brain; Cerebrovascular Circulation; Combined Modality Therapy; Dou | 2000 |
Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study.
Topics: Aspirin; Blood Platelets; Demography; Double-Blind Method; Endpoint Determination; Female; Follow-Up | 2000 |
Restitution of alpha-topography by piracetam in post-stroke aphasia.
Topics: Adult; Aged; Analysis of Variance; Aphasia; Brain Mapping; Double-Blind Method; Electroencephalograp | 2001 |
Other Studies
22 other studies available for piracetam and Stroke
| Article | Year |
|---|---|
Herpes simplex encephalitis presenting as stroke-like symptoms with atypical MRI findings and lacking cerebrospinal fluid pleocytosis.
Topics: Acyclovir; Aged; Antiviral Agents; Biomarkers; Brain; Clonazepam; DNA, Viral; Drug Therapy, Combinat | 2017 |
[A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Japan; Levetiracetam; Male; Piracetam; Sei | 2018 |
Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Levetiracetam; Long QT Syndrome; Male; Mid | 2014 |
Neurofibromatosis 1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like symptoms.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Antiviral Agents; Brain Diseases; Cafe-au-Lait Spots; | 2015 |
Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model.
Topics: Animals; Animals, Newborn; Anticonvulsants; Brain; Brain Ischemia; Disease Models, Animal; Epilepsy; | 2017 |
Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke.
Topics: Aged; Brain Ischemia; Central Nervous System Stimulants; Cerebral Infarction; Cerebrovascular Circul | 2008 |
Publication bias perpetuates use of ineffective drugs in stroke.
Topics: Fibrinolytic Agents; Humans; Nadroparin; Nootropic Agents; Piracetam; Publication Bias; Research Des | 2009 |
[Use of omaron in patients with post-stroke cognitive disorders].
Topics: Administration, Oral; Aged; Cinnarizine; Cognition; Cognition Disorders; Dose-Response Relationship, | 2009 |
[Omaron in the rehabilitation of post stroke outpatients].
Topics: Calcium Channel Blockers; Cinnarizine; Drug Combinations; Humans; Neuroprotective Agents; Piracetam; | 2010 |
Neuroprotection in post-stroke epilepsy: a realistic goal?
Topics: Anticonvulsants; Epilepsy; Female; Humans; Male; Piracetam; Randomized Controlled Trials as Topic; S | 2011 |
Postpartum cerebral venous thrombosis.
Topics: Anticoagulants; Anticonvulsants; Brain; Female; Heparin; Humans; Hypertension; Levetiracetam; Magnes | 2011 |
A case of physical and mental adverse drug reactions associated with levetiracetam in post-stroke epilepsy.
Topics: Aged; Anticonvulsants; Cognition; Disease Progression; Drug-Related Side Effects and Adverse Reactio | 2012 |
[Prolonged hemiplegia as the only symptom of a simple focal nonconvulsive status epilepticus].
Topics: Anticonvulsants; Bacteriuria; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Electro | 2012 |
[The results of the use of levetiracetam (keppra) in post-stroke epilepsy].
Topics: Aged; Anticonvulsants; Epilepsies, Partial; Female; Humans; Levetiracetam; Male; Middle Aged; Pirace | 2012 |
[Does treatment with piracetam in stroke patients with aphasia make sense?].
Topics: Aphasia; Humans; Neuroprotective Agents; Nootropic Agents; Piracetam; Stroke | 2002 |
Neuroprotective effects on somatotopic maps resulting from piracetam treatment and environmental enrichment after focal cortical injury.
Topics: Animals; Brain Mapping; Disease Models, Animal; Electrophysiology; Environment, Controlled; Forelimb | 2003 |
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem | 2007 |
[Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs].
Topics: Amino Acids; Animals; Brain; Brain Ischemia; Glycerylphosphorylcholine; Male; Neuroprotective Agents | 2006 |
[The management of stroke in Phnom Penh, Cambodia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Calcium Channe | 2007 |
Levetiracetam use in critically ill patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Diseases; Brain Ne | 2007 |
Changes at the focus of experimental ischemic stroke treated with neuroprotective agents.
Topics: Amino Acids; Animals; Brain; Brain Ischemia; Glycerylphosphorylcholine; Male; Neuroprotective Agents | 2008 |
Acute stroke management in the local general hospital.
Topics: Diuretics; Echocardiography; Electrocardiography; Germany; Health Resources; Hospitals, Community; H | 2001 |